Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.

Clinical evaluation of class I medical devices

The Swedish Medtech Regulatory Summit is just around the corner — taking place on March 12th at Hilton Slussen in Stockholm. We’re proud to share that our Senio...

Investor Network Backs Early-Stage Nordic Innovation

Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested...

Gene therapies on clinical hold after tumour found in five‑year‑old

The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio,...

A food-based strategy to stop gut infections early

Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier b...

End of bone‑sawing? New laser cuts to record depths

Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have disc...

Novo Nordisk Foundation commits billions to Danish life science incubator

The Novo Nordisk Foundation grants up to DKK 5.5 billion to life science and deep‑tech incubator Bioinnovation Institute (BII) in Copenhagen.

Genmab drops another ADC candidate from billion‑dollar ProfoundBio deal

Danish biotech Genmab has discontinued development of its antibody‑drug conjugate (ADC) candidate GEN1160, citing low patient enrollment in an early‑stage cancer trial.

Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”

With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.

FDA leaders seek to scrap two-study requirement

A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Mak...

Study: Autism as common in girls as in boys

Autism may be just as common in girls as in boys, but girls are diagnosed significantly later and less often during childhood, according to a large Swedish registry study.

Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”

The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a r...

Asgard teaches tumours to self‑destruct – moving closer to clinical trials

Swedish biotech Asgard Therapeutics not only has an evocative name, but also a remarkably exciting approach to cancer treatment: getting tumour cells to reprogr...

Microscope and measuring machine in one

ZEISS O-INSPECT duo covers two essential applications in quality assurance.

Acne medication may be the solution when hair starts falling out

A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.

Novo Nordisk strengthens board after turbulent year

Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with ex...

Obesity dominates as future blockbusters are identified

Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.

Gothenburg-based Anyo Labs gains ground in the AI race

In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

Merck Life Science A/S

Lonza

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA

ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...